混合型冷球蛋白血症的长期结局与预后:欧洲多中心1294例研究
该欧洲多中心队列研究纳入1294例全病因混合型冷球蛋白血症血管炎(CryoVas)患者,中位随访2.8年。HCV为最主要病因(36%),其次为特发性(26%)和自身免疫病(23%)。多因素模型显示2014年后诊断、男性、高龄、低C4、类风湿因子阳性及高基线肌酐为不良预后因素,HCV病因具保护性;淋巴瘤发生与2014年后诊断、自身免疫病因、发热、乏力及低C4相关。
要点
- HCV是CryoVas最常见病因,但自身免疫病因者病程更重、淋巴瘤风险更高。
- 低C4水平、类风湿因子阳性及高基线肌酐是不良预后的独立因素。
- 2014年后诊断、自身免疫病因、发热、乏力及低C4与淋巴瘤发生相关。
核心结论
- HCV病因在CryoVas中具保护性,而自身免疫病因者病程更重且淋巴瘤风险更高。
研究设计与样本
- 欧洲多中心队列研究(EuroCryo),纳入1294例全病因混合型冷球蛋白血症血管炎患者。
主要发现
- 中位随访2.8年,558例患者共发生661起严重事件,包括221例复发、52例严重感染和45例淋巴瘤。
- 多因素模型显示2014年后诊断、男性、高龄、低C4水平、类风湿因子阳性及较高基线肌酐水平为不良预后因素,HCV病因具保护性。
- 淋巴瘤发生相关因素包括2014年后诊断、自身免疫病因、发热、乏力及低C4水平。
关键数值与推荐
- 主要病因:HCV 469例(36%),特发性344例(26%),自身免疫病302例(23%),其中干燥综合征最常见(268例,21%)。
临床怎么用
- 对CryoVas患者应评估病因,自身免疫病因者需警惕更重病程及淋巴瘤风险。
- 低C4、类风湿因子阳性及高基线肌酐提示预后不良,应加强监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the long-term outcomes and prognostic factors of patients presenting with all-cause mixed cryoglobulinaemia vasculitis (CryoVas). METHODS: A European multicentre cohort study (EuroCryo) of 1294 patients presenting with all-cause CryoVas. RESULTS: The main aetiology for CryoVas was Hepatitis C Virus ( HCV) with 469 (36%) cases, followed by essential forms (n = 344, 26%) and autoimmune conditions (n = 302, 23%), with Sjögren's disease being the most common (n = 268, 21%). Over a median follow-up of 2.8 years, a total of 558 CryoVas patients experienced 661 severe events, notably 221 relapses, 52 severe infections and 45 lymphomas. The multivariable model for event-free survival retained a post-2014 diagnosis, male sex, older age, low C4 levels, positive Rheumatoid Factor and higher baseline creatinine levels as poor prognostic factors; HCV aetiology was protective. Factors associated with the occurrence of lymphoma were a post-2014 diagnosis, autoimmune aetiology, fever, fatigue and low C4 levels. CONCLUSION: HCV was for long considered a poor prognosis factor in CryoVas, and now those secondary to autoimmune conditions seem to evolve with a more severe course, notably carrying a higher lymphoma risk.
引用
- Saadoun D, Cacoub P, Retamozo S, et al. Long-term outcomes and prognosis of mixed cryoglobulinaemia: a European multicentre study of 1294 patients. Rheumatology (Oxford). 2026. PMID: 42316808. doi:10.1093/rheumatology/keag264
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。